BRAF and colorectal cancer: A recent cellular screen identified YAP1 activation as a novel mechanism of resistance to the triple combination of EGFR, BRAF and MEK inhibitors cetuximab, dabrafenib and trametinib in BRAF mutant colorectal cancer cell lines [41], which is in line with studies showing that the knockdown of YAP1 increases sensitivity to mitogen-activated protein kinase (MAPK) pathway inhibitors [42].